Advertisement

Acta Biologica Hungarica

, Volume 58, Issue 1, pp 49–59 | Cite as

Evaluation of the Effect of Paclitaxel, Epirubicin and Tamoxifen by Cell Kinetics Parameters in Estrogen-Receptor-Positive Ehrlich Ascites Tumor (Eat) Cells Growing in vitro

  • G. Özcan AricanEmail author
  • A. Özalpan
Article

Abstract

In this study the antiproliferative effects of Paclitaxel (PAC), Epirubicin (EPI) and Tamoxifen (TAM) on growth kinetics of Ehrlich Ascites Tumor (EAT) cells were examined in culture. An estrogen-receptor-positive ER (+) hyperdiploid EAT cell line growing in vitro was also analysed in the present study. IC50 doses of PAC, EPI and TAM (12 μg/ml, 12 μg/ml and 2 μg/ml, respectively) were used. Cells were treated with the above doses for 0, 4, 8, 16, 24 and 32 hrs. At the end of these periods, living cell numbers were determined by collecting EAT cells in every group for growth study rate and for MTT assay. Therefore, the mitotic index was determined in the same experimental groups. The proliferation of EAT cells, inhibited by PAC, EPI and TAM concentrations was compared to control with increasing treatment time (4–32 hrs). Treatment of PAC, EPI and TAM alone for 24 hrs decreased the proliferation rate of EAT cells by 50% with respect to control. The inhibition of proliferation rate was higher in double drug treatment than that in single drug treatment with increased treatment time. In the treatment of three drugs applied for 32 hrs, this effect reached a maximum and proliferation rate decreased by 12% as compared to the (100%) control. In our studies, when the mitotic index parameter data were evaluated to determine which phase of the cell cycle was affected by PAC to cause the repression of cell reproduction, it was found that PAC exerted of its cytotoxic effect by causing cell accumulation at mitosis. The accumulation of the cells resulted in an increase in mitotic index values, which was an expected consequence of PAC treatment. It was observed that depending on the drug treatments, inhibition of proliferation rate and mitotic index in EAT cells were increased with respect to control, being with statistically significant occurrence (p < 0.01 - p < 0.001). As a result, concomitant treatment combined with hormonal therapy has given improved results compared with single treatment and PAC+EPI+TAM treatments had a maximum synergistic effect for 32 hrs (p < 0.001).

Keywords

EAT cells cell kinetics Paclitaxel Epirubicin Tamoxifen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgments

This work was supported by the Research Fund of Istanbul University. Project no: B-757/12092000.

References

  1. 1.
    Aydıner, A., Rıdvanoğulları, M., Anıl, D., Topuz, E., Nurten, R., Disci, R. (1997) Combined effects of epirubicin and tamoxifen on the cell-cycle phases in estrogen-receptor-negative Ehrlich ascites tumor cells. J. Cancer Res. Clin. Oncol. 123, 113–117.CrossRefGoogle Scholar
  2. 2.
    Clarke, R. B., Laidlaw, I. J., Jones, L. J., Howell, A., Anderson, E. (1993) Effect of tamoxifen on Ki67 labelling index in human breast tumors and its relationship to estrogen progesterone receptor status. Br. J. Cancer 67, 606–611.CrossRefGoogle Scholar
  3. 3.
    Cuzick, J., Baum, M. (1985) Tamoxifen and contralateral breast cancer. Lancet 2 (8449), 282.Google Scholar
  4. 4.
    Gullino, P. M., Pettigrew, H. N., Grantham, F. H. (1975) N-Nitrosomethylurea as mammary gland carcinogen in rats. J. Nat. Cancer Inst. 54, 401–414.PubMedGoogle Scholar
  5. 5.
    Hill, B. T., Whelan, R. D. H. (1982) A comparison of the lethal and kinetics effects of doxorubicin and 4’-epidoxorubicin in vitro. Tumori 68, 29–37.CrossRefGoogle Scholar
  6. 6.
    Holmes, F. A., Walters, R. S., Theriault, R. L., Forman, A. D., Newton, L. K., Raber, M. N., Buzdar, A. U., Frye, D. K., Hortobagyi, G. N. (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Nat. Cancer Inst. 83, 1797–1805.CrossRefGoogle Scholar
  7. 7.
    Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., Wilson L. (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56, 816–825.PubMedGoogle Scholar
  8. 8.
    Kennedy, D. O., Kojima, A., Moffat, J., Yamagiwa, H., Yano, Y. (2002) Cellular thiol status-dependent inhibition of tumor cell growth via modulation of retinoblastoma protein phosphorylation by (-)-epigallocatechin. Cancer Lett. 179, 25–32.CrossRefGoogle Scholar
  9. 9.
    Klotz, I. M. (1982) Number of receptor sites from Scatchard graphs, facts and fantasies. Science 217, 1247–1249.CrossRefGoogle Scholar
  10. 10.
    Lippman, M., Huff, K. A. (1976) A demonstration of androgen and estrogen in a human breast cancer using a new protamine sulfate assay. Cancer. 38, 868–874.CrossRefGoogle Scholar
  11. 11.
    Long, B. H., Fairchild, C. R. (1994) Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res. 54, 4355–4361.PubMedGoogle Scholar
  12. 12.
    Lu, K. H., Lue, K. H., Chou, M. C., Chung, J. G. (2005) Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 os). J. Orthopaedic Res. 23, 988–994.CrossRefGoogle Scholar
  13. 13.
    Mc Guire, W. L., Horwitz, K. B., Zava, D. T., Garola, R. E., Chamness, G. C. (1978) Hormones in breast cancer. Metabolism 27, 487–501.CrossRefGoogle Scholar
  14. 14.
    McGuire, W. L., Tandon, A. K., Allred, D. C., Chamness, G. C., Mc Clark, G. M. (1990) How to use prognostic factors in axillary node-negative breast cancer patients. J. Nat. Cancer Inst. 82, 1006–1015.CrossRefGoogle Scholar
  15. 15.
    Mondal, T. K., Bhatta, D. (2002) Superantigen-induced death of tumor cells is mediated by cytotox-ic lymphocytes, cytokines, and nitric oxide. Biochem. Biophys. Res. Commun. 290, 1336–1342.CrossRefGoogle Scholar
  16. 16.
    Mosmann, T. (1983) Rapid Colorimetric Assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Meth. 65, 55–63.CrossRefGoogle Scholar
  17. 17.
    Norton, L., Seidman, A. (1992) Taxol plus recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. 2nd Natl. Cancer Inst. Workshop on Taxol and Taxus, Alexandria VA., pp. 23-24.Google Scholar
  18. 18.
    Osborne, C. K. (1994) Interactions of tamoxifen with cytotoxic chemotherapy for breast cancer. Long term tamoxifen for breast cancer. In: Jordan, V. C. (ed.) Long Term Tamoxifen for Breast Cancer. Wisconsin University Press, Madison., pp. 181–198.Google Scholar
  19. 19.
    Osborne, C. K., Bold, D. H., Clark, G. M., Trent, J. M. (1983) Effect of tamoxifen on human breast cancer cell cycle kinetics. Accumulation of cells in early G1 phase. Cancer Res. 43, 3583–3585.PubMedGoogle Scholar
  20. 20.
    Osborne, C. K., Kitten, L., Arteaga, C. L. (1989) Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J. Clin. Oncol. 7, 710–717.CrossRefGoogle Scholar
  21. 21.
    Özcan Arıcan, G. (2005) Cytoprotective effects of amifostine and cysteamine on cultured normal and tumor cells treated with paclitaxel in terms of mitotic index and 3H-thymidine labeling index. Cancer Chemother. Pharmacol. 56, 221–229.CrossRefGoogle Scholar
  22. 22.
    Özcan Arıcan, G., Topçul, M. R. (2003) Effect of epirubicin on mitotic index in cultured L-cells. J. Cell and Molecular Biol. 2, 43–48.Google Scholar
  23. 23.
    Özcan, F. G., Topçul, M. R., Yılmazer, N., Rıdvanoğulları, M. (1997) Effect of epirubicin on 3H-thymidine labelling index in cultured L-strain cells. J. Exp. Clin. Cancer Res. 16, 23–27.PubMedGoogle Scholar
  24. 24.
    Pigram, W. J., Fuller, W., Hamilton, L. D. (1972) Stereochemistry of interaction: Interaction of daunomycin with DNA. Nat. New Biol. 235, 17–19.CrossRefGoogle Scholar
  25. 25.
    Plosker, G. L., Faulds, D. (1993) Epirubicin. A review of its pharmacodynamic and pharmacokinet-ic properties, and therapeutic use in cancer chemotherapy. Drugs 45, 788–856.CrossRefGoogle Scholar
  26. 26.
    Raynaud, J. P., Martin, P. M., Bouton, M. M., Ojasoo, T. (1978) 11-beta-Methoxy-17-ethynyl-1,3,5(10)-estratrience-3,17-beta-diol, a tag for estrogen receptor binding sites in human tissues. Cancer Res. 38, 3044–3050.PubMedGoogle Scholar
  27. 27.
    Rowinsky, E. K., Onetto, N., Canetta, R. M., Arbuck, S. G. (1992) Taxol: The first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 19, 646–662.PubMedGoogle Scholar
  28. 28.
    Schiff, P. B., Horwitz S. B. (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Cell Biol. 77, 1561–1565.Google Scholar
  29. 29.
    Stewart, H. L., Snell, K. C., Dunham, L. J., Schleyen, S. M. (1959) V2 carcinoma, rabbit. In: Atlas of Tumor Pathology, Transplantable and Transmissible Tumors of Animals. Section XII, fascicle 40. AFIP, Washington D. C., pp. 38–42.Google Scholar
  30. 30.
    Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., Liu, L. F. (1984) Adriamycin induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226, 466–468.CrossRefGoogle Scholar
  31. 31.
    Wang, T. H., Wang, H.-S., Soong, Y. K. (2000) Paclitaxel-induced cell death. Where the cell cycle and apoptosis come together. Cancer 88, 2619–2628.CrossRefGoogle Scholar
  32. 32.
    Zar, J. H. (1984) Biostatistical Analysis. 2nd Edition. Prentice-Hall Inc, Englewood Cliffs, New Jersey.Google Scholar

Copyright information

© Akadémiai Kiadó, Budapest 2007

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Biology Department, Science FacultyIstanbul UniversityIstanbulTurkey
  2. 2.Faculty of Science and LettersIstanbul Kültür UniversityIstanbulTurkey

Personalised recommendations